Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1588-1597

  Marschall, Manfred ^a,b   Freitag, Martina ^a   Weiler, Sigrid ^a   Sorg, Gabriele ^a   Stamminger, Thomas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GREEN FLUORESCENT PROTEIN;

ARTICLE; CELL CULTURE; DRUG DETERMINATION; FLOW CYTOMETRY; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REPRODUCIBILITY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; DRUG EVALUATION, PRECLINICAL; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; RECOMBINATION, GENETIC;

EID: 0034036546     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1588-1597.2000     Document Type: Article

References (36)

1. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 1998. Current protocols in molecular biology. John Wiley & Sons, Inc., New York, N.Y.
2. Azad, R. F., V. Brown-Driver, R. W. Buckheit, Jr., and K. P. Anderson. 1995. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res. 28:101-111.
3. Baldanti, F., E. Silini, A. Sarasini, C. L. Talarico, S. C. Stanat, K. K. Biron, M. Furione, F. Bono, G. Palu, and G. Gerna. 1995. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J. Virol. 69:796-800.
4. Bevilacqua, F., N. Davis-Poynter, J. Worrallo, D. Gower, P. Collins, and G. Darby. 1995. Construction of a herpes simplex virus/varicella-zoster virus (HSV/VZV) thymidine kinase recombinant with the pathogenic potential of HSV and a drug sensitivity profile resembling that of VZV. J. Gen. Virol. 76:1927-1935.
5. Borst, E.-M., G. Hahn, U. H. Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
6. Britt, J. B., and C. A. Alford. 1996. Cytomegaloviruses, p. 2493-2523. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven Publishers, Philadelphia, Pa.
7. Cherrington, J. M., M. D. Fuller, P. D. Lamy, R. Miner, J. P. Lalezari, S. Nuessle, and W. L. Drew. 1998. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first-or second-line cidofovir therapy: relationship to clinical outcome. J. Infect. Dis. 178:1821-1825.
8. Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
9. Chulay, J., K. Biron, L. Wang, M. Underwood, S. Chamberlain, L. Frick, S. Good, M. Davis, R. Harvey, L. Townsend, J. Drach, and G. Koszalka. 1999. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv. Exp. Med. Biol. 458:129-134.
10. Dankner, W. M., D. Scholl, S. C. Stanat, M. Martin, R. L. Sonke, and S. A. Spector. 1990. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J. Virol. Methods 28:293-298.
11. Erice, A., N. Borrell, W. Li, W. J. Miller, and H. H. Balfour, Jr. 1998. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J. Infect. Dis. 178:531-534.
12. Fleckenstein, B., I. Müller, and J. Collins. 1982. Cloning of the complete human cytomegalovirus genome in cosmids. Gene 18:39-46.
13. Jacobson, M. A. 1994. Current management of cytomegalovirus disease in patients with AIDS. AIDS Res. Hum. Retrovir. 10:917-923.
14. Jones, T. R., V. P. Muzithras, and Y. Gluzman. 1991. Replacement mutagenesis of the human cytomegalovirus genome: US10 and US11 gene products are nonessential. J. Virol. 65:5860-5872.
15. Jons, A., and T. C. Mettenleiter. 1997. Green fluorescent protein expressed by recombinant pseudorabies virus as an in vivo marker for viral replication. J. Virol. Methods 66:283-292.
16. Kesson, A. M., F. Zeng, A. L. Cunningham, and W. D. Rawlinson. 1998. The use of flow cytometry to detect antiviral resistance in human cytomegalovirus. J. Virol. Methods 71:177-186.
17. Kohler, C. P., J. A. Kerry, M. Carter, V. P. Muzithras, T. R. Jones, and R. M. Stenberg. 1994. Use of recombinant virus to assess human cytomegalovirus early and late promoters in the context of the viral genome. J. Virol. 68: 6589-6597.
18. Krosky, P. M., M. R. Underwood, S. T. Turk, K. W.-H. Feng, R. K. Jain, R. G. Ptak, A. C. Westerman, K. K. Biron, L. B. Townsend, and J. C. Drach. 1998. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
19. Lalezari, J. P. 1997. Cidofovir: a new therapy for cytomegalovirus retinitis. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14(Suppl. 1):22-26.
20. Maidji, E., S. Tugizov, T. Jones, Z. Zheng, and L. Pereira. 1996. Accessory human cytomegalovirus glycoprotein US9 in the unique short component of the viral genome promotes cell-to-cell transmission of virus in polarized epithelial cells. J. Virol. 70:8402-8410.
21. Marschall, M., P. Alliger, F. Schwarzmann, C. Bogedain, M. Brand, B. Reichelt, G. Glaser, and H. Wolf. 1993. The lytic transition of Epstein-Barr virus is imitated by recombinant B cells. Arch. Virol. 129:23-33.
22. McSharry, J. J., N. S. Lurain, G. L. Drusano, A. L. Landay, M. Notka, M. R. G. O'Gorman, A. Weinberg, H. M. Shapiro, P. S. Reichelderfer, and C. S. Crumpacker. 1998. Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 42:2326-2331.
23. Messerle, M., I. Crnkovic, W. Hammerschmidt, H. Ziegler, and U. H. Koszinowski. 1997. Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc. Natl. Acad. Sci. USA 94: 14759-14763.
24. Mocarski, E. S., Jr. 1996. Cytomegaloviruses and their replication, p. 2447-2492. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven Publishers, Philadelphia, Pa.
25. Mulamba, G. B., A. Hu, R. F. Azad, K. P. Anderson, and D. M. Coen. 1998. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 42:971-973.
26. Perry, C. M., and J. A. Balfour. 1999. Fomivirsen. Drugs 57:375-380.
27. Polis, M. A., K. M. Spooner, B. F. Baird, J. F. Manischewitz, H. S. Jaffe, P. E. Fisher, J. Fallon, R. T. Davey, Jr., J. A. Kovacs, R. E. Walker, S. M. Whitcup, R. B. Nussenblatt, H. C. Lane, and H. Masur. 1995. Anticytomegaloviral activity and safety of cidifovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother. 39: 882-886.
28. Prix, L., J. Maierl, G. Jahn, and K. Hamprecht. 1998. A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains. J. Clin. Virol. 11:29-37.
29. Schmolke, S., H. F. Kern, P. Drescher, G. Jahn, and B. Plachter. 1995. The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J. Virol. 69:5959-5968.
30. Smith, I. L., J. M. Cherrington, R. E. Jiles, M. D. Fuller, W. R. Freeman, and S. A. Spector. 1998. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:69-77.
31. Sorg, G., and T. Stamminger. 1998. Strong conservation of the constitutive activity of the IE1/2 transcriptional control region in wild-type strains of human cytomegalovirus. J. Gen. Virol. 79:3039-3047.
32. Spaete, R. R., and E. S. Mocarski. 1987. Insertion and deletion mutagenesis of the human cytomegalovirus genome. Proc. Natl. Acad. Sci. USA 84:7213-7217.
33. Underwood, M. R., R. J. Harvey, S. C. Stanat, M. L. Hemphill, T. Miller, J. C. Drach, L. B. Townsend, and K. K. Biron. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-725.
34. Vieira, J., T. J. Schall, L. Corey, and A. P. Geballe. 1998. Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene. J. Virol. 72:8158-8165.
35. Waldman, W. J., D. A. Knight, N. S. Lurain, D. M. Miller, D. D. Sedmak, J. W. Williams, and A. S.-F. Chong. 1999. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 68:814-826.
36. Zolotukhin, S., M. Potter, W. W. Hauswirth, J. Guy, and N. Muzyczka. 1996. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J. Virol. 70:4646-4654.